Grifols SA 2025 IR
The report highlights Grifols' financial and operational performance in 2025, achieving revenues of over EUR 7,500 million and an adjusted EBITDA of EUR 1,825 million. The company made significant progress in its strategic self-sufficiency projects in Canada and Egypt, with the latter achieving clinical self-sufficiency in key plasma-derived medicines. On the environmental front, Grifols reduced its Scope 2 emissions by 49% and increased its renewable electricity consumption to 56%. Additionally, the company was awarded the EcoVadis Platinum medal, placing it in the top 1% of the world's most sustainable companies.
Company: Grifols SA
Sector: Health Care
Country: Spain
Year: 2025
Type: IR
Pages: 274
Grifols SA
Integrated Annual Report
The report highlights Grifols' financial and operational performance in 2025, achieving revenues of over EUR 7,500 million and an adjusted EBITDA of EUR 1,825 million. The company made significant progress in its strategic self-sufficiency projects in Canada and Egypt, with the latter achieving clinical self-sufficiency in key plasma-derived medicines. On the environmental front, Grifols reduced its Scope 2 emissions by 49% and increased its renewable electricity consumption to 56%. Additionally, the company was awarded the EcoVadis Platinum medal, placing it in the top 1% of the world's most sustainable companies.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees